ACET — Adicet Bio Cashflow Statement
0.000.00%
Last trade - 00:00
- $101.90m
- -$145.69m
- 17
- 49
- 28
- 22
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -82.7 | -36.7 | -62 | -69.8 | -143 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 2.73 | 7.42 | 15.5 | 19.7 | 42.6 |
Unusual Items | |||||
Purchased R&D | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 6.21 | -13.3 | -6.05 | 2.74 | 0.252 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -73.7 | -41.6 | -51.1 | -44.8 | -93.7 |
Capital Expenditures | -0.271 | -0.99 | -13 | -16.8 | -4.46 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 44.4 | 116 | 10.3 | 0 | — |
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 44.1 | 115 | -2.8 | -16.8 | -4.46 |
Financing Cash Flow Items | -0.02 | -0.157 | -0.261 | -3.6 | -0.15 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 56.4 | 0.303 | 243 | 41.5 | 0.236 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 26.9 | 74 | 189 | -20 | -97.9 |